Skip to main content
. 2014 Nov 10;349:g5981. doi: 10.1136/bmj.g5981

Table 1.

Selected data from three multicentre trials of HES

First author Population studied No enrolled Test group Control No (%) with outcome (intervention v control)
28 day mortality 90 day mortality Requiring renal replacement therapy Use of blood products
Brunkhorst1 Severe sepsis 600 10% HES 200/0.5 Ringer’s lactate 70/262 (26.7) v 66/274 (24.1), P=0.48 107/261 (41.0) v 93/274 (33.9), P=0.09 81/261 (31.0) v 51/272 (18.8), P=0.001* Exposure to red cell transfusions (over 21 days): 189/275 (68.7) v199/262 (76), P=0.06
Myburgh2 Intensive care 7000 6% HES 130/0.4 0.9% NaCl 458/3313 (13.8) v 437/3331 (13.1), P=0.40 597/3315 (18.0) v 566/3336 (17.0), P=0.26 235/3352 (7.0) v 196/3375 (5.8), P=0.04† Mean (SD) daily volume of blood products (first four days): 78 (250) ml v 60 (190) mL, P<0.001
Perner3 Severe sepsis 804 6% HES 130/0.4 Ringer’s acetate 154/398 (38.7) v 144/400 (36.0), P=0.43 201/398 (50.5) v 172/400 (43.0); P=0.03 87/398 (21.9) v 65/400 (16.3), P=0.04† Exposure to blood product transfusion: 243/376 (64.6) v 204/380 (53.7), P=0.003
Severe bleeding (clinical bleeding requiring ≥3 units of packed red cells within 24 hours) 38/398 (9.5) v 25/400 (6.3), P=0.09

*At 21 days.

†At 90 days.